Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zarxio,ZarxioStudy001,2021,USA,MDV,350,62,45,55,27.5,32,85,12,25,35,20,10,60,25,10,5,30,40,20,15,8,3,7,4,22,48,35,FAC,TC,AC,CMF,28,32,25,18,65,55,15,45,40,60,2
Zarxio,ZarxioStudy002,2022,Canada,Claim Database,420,68,52,48,28.1,28,78,15,20,40,25,5,55,30,10,5,25,45,25,18,10,4,9,5,25,52,40,TC,EC,CMF,Taxol,30,35,20,20,70,60,10,50,40,65,3
Zarxio,ZarxioStudy003,2023,UK,MDV,280,70,48,52,26.9,35,75,18,15,38,30,7,50,35,10,5,20,42,28,20,12,5,10,6,28,55,42,EC,Docetaxel,Taxol,FEC,32,38,18,22,72,62,8,52,40,70,4
